Cash receipts for CUV have been FY 2020 32.65million, FY2021...

Cash receipts for CUV have been FY 2020 32.65million, FY2021 38.72 million and FY22 66.4 million. That's more than a 100% increase over two years. Costs are strongly controlled and the company is debt free. In times of high inflation it's very reassuring to have no debt on your balance sheet and to be generating increasing amounts of cash. The free cashflow generated is strong which is being used to fund their trials and hopes for significant future revenue streams. The management is very risk averse which is certainly appropriate in the current economic and market conditions. The company is pursuing exactly what it said it would do.
Because the company only has around 50 million shares on issue which are reasonably tightly held, the share price can be moved up and down quite significantly by low volumes of trading. In recent times (the last 10 months) most CUV announcements have been a catalyst for the shares to be sold off. Prior to that they were a catalyst for for the shares to surge forward. That's why they reached $44 not that long ago. The underlying business is stronger now that it was both one year and two years ago. Share prices fluctuate for all sorts of reasons but eventually they reflect the underlying value of the business. For CUV it's PE has fluctuated from around 100 to around 30 now, that's quite a compression.